Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics (Glitz Asthma) (GLITZ)
Asthmatics who are significantly overweight tend to have more severe symptoms, more flare ups, and are more likely to have poorly-controlled asthma when compared to other asthmatics.
Researchers believe this occurs because excess adipose tissue (fat) in the bosy can cause higher-than-normal levels of leptin and lower levels of adiponectin in the blood.
The researchers of this study are testing a medication called pioglitazone in overweight asthmatics because they believe it can help regulate leptin and adiponectin and that this may improve symptoms of asthma.
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||A Randomized, Placebo-Controlled Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics. (The GLITZ Asthma Study)|
- PC20 [ Time Frame: 12 weeks ]
Airway reactivity will be measured with methacholine challenge testing following ATS guidelines.
This is the concentration of methacholine that produces a 20% decrease in lung function (measured by forced expiratory volume in 1 second)
|Study Start Date:||January 2009|
|Study Completion Date:||December 2013|
|Primary Completion Date:||June 2013 (Final data collection date for primary outcome measure)|
|Active Comparator: 1||
Pioglitazone tablets; 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)
|Placebo Comparator: 2||
Matching placebo (inert tablet)
Participants in this study will be randomly assigned (like the flip of a coin) to pioglitazone or placebo (an inactive pill). They will be given study medication to take every day for 12 weeks (3 months).
Participants will complete a number of asthma-related questionnaires and a variety of pulmonary function tests. Participants will undergo physical exams, an electrocardiogram, and blood sampling to measure leptin, adiponectin, markers of inflammation, blood cell counts, glucose levels, BNP hormone levels, and liver function.
To monitor participants throughout the study, follow-up visits will be done at 2, 6, and 12 weeks after starting study drug. At these visits many of the pulmonary function tests and questionnaires will be repeated.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00787644
|United States, Vermont|
|The Vermont Lung Center at the University of Vermont|
|Colchester, Vermont, United States, 05446|
|Principal Investigator:||Anne E Dixon, MD||The Vermont Lung Center at the University of Vermont|